This Article Full Text Full Text (PDF) CME: Take the course for this article: An Update on Hepatic Arterial Infusion Chemotherapy for Colorectal Cancer eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cohen, A. D. Articles by Kemeny, N. E. Search for Related Content PubMed PubMed Citation Articles by Cohen, A. D. Articles by Kemeny, N. E.

An Update on Hepatic Arterial Infusion Chemotherapy for Colorectal Cancer

Gastrointestinal Oncology Service, Solid Tumor Division, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA

Correspondence: Nancy E. Kemeny, M.D., Memorial Sloan-Kettering Cancer Center, Gastrointestinal Oncology Service, 1275 York Avenue, New York, New York 10021, USA. Telephone: 212-639-8068; Fax: 212-639-8794; e-mail: Kemenyn{at}mskcc.org

Hepatic metastases are a frequent complication of colorectal cancer (CRC), affecting over half of all CRC patients. Resection of isolated metastases can result in long-term survival, but the majority of patients relapse, and most have unresectable disease. Hepatic arterial infusion (HAI) chemotherapy delivers high concentrations of cytotoxic agents directly to liver metastases with minimal systemic toxicities. Advances in surgical techniques, development of fully implantable pumps, and modification of drug regimens have decreased complications and improved patient tolerability. Randomized trials comparing HAI with systemic chemotherapy have demonstrated superior response rates and times to hepatic progression for unresectable disease, and have shown better times to progression and overall survival rates in the adjuvant setting following hepatic resection. HAI chemotherapy has unique toxicities, including chemical hepatitis and biliary sclerosis, which can be mitigated by the addition of dexamethasone to therapy. In an attempt to prevent extrahepatic progression, combinations of HAI with systemic chemotherapy, including newer agents such as irinotecan and oxaliplatin, are currently being investigated, with promising early results.

Key Words. Hepatic arterial infusion • Chemotherapy • Floxuridine • Colorectal cancer • Randomized trials

This article has been cited by other articles:

				S. Mocellin and D. Nitti In Reply J. Clin. Oncol., June 1, 2008; 26(16): 2789 - 2790. [Full Text] [PDF]

				S. Mocellin, P. Pilati, M. Lise, and D. Nitti Meta-Analysis of Hepatic Arterial Infusion for Unresectable Liver Metastases From Colorectal Cancer: The End of an Era? J. Clin. Oncol., December 10, 2007; 25(35): 5649 - 5654. [Abstract] [Full Text] [PDF]

				G. Portier, D. Elias, O. Bouche, P. Rougier, J.-F. Bosset, J. Saric, J. Belghiti, P. Piedbois, R. Guimbaud, B. Nordlinger, et al. Multicenter Randomized Trial of Adjuvant Fluorouracil and Folinic Acid Compared With Surgery Alone After Resection of Colorectal Liver Metastases: FFCD ACHBTH AURC 9002 Trial J. Clin. Oncol., November 1, 2006; 24(31): 4976 - 4982. [Abstract] [Full Text] [PDF]

				H. Seki and M. Shiina Placement of a long tapered side-hole catheter in the hepatic artery: technical advantages, catheter stability, and arterial patency. Am. J. Roentgenol., November 1, 2006; 187(5): 1312 - 1320. [Abstract] [Full Text] [PDF]

				D. L. Bartlett, J. Berlin, G. Y. Lauwers, W. A. Messersmith, N. J. Petrelli, and A. P. Venook Chemotherapy and Regional Therapy of Hepatic Colorectal Metastases: Expert Consensus Statement Ann. Surg. Oncol., October 1, 2006; 13(10): 1284 - 1292. [Full Text] [PDF]